*The following content is generated by AI and is for reference only.
Sarpogrelate hydrochloride is a selective serotonin 5-HT2A receptor antagonist primarily utilized in the management of peripheral arterial occlusive diseases. Its chemical identity is defined by the molecular formula C26H30ClN3O4, with a corresponding CAS registry number of 98798-15-1. Structurally, this compound belongs to the benzazepine class and functions by blocking serotonin-induced platelet aggregation and vasoconstriction. Unlike non-selective antiplatelet agents such as aspirin, Sarpogrelate specifically targets the 5-HT2A receptors located on both platelets and vascular smooth muscle cells. This dual mechanism effectively inhibits thrombus formation while simultaneously promoting vasodilation, thereby improving blood flow to ischemic extremities.
Clinically, Sarpogrelate is widely prescribed for conditions characterized by intermittent claudication, rest pain, and trophic ulcers associated with chronic arterial insufficiency. It is particularly valuable in treating patients who cannot tolerate aspirin or require adjunctive therapy to enhance microcirculation. By reducing vascular resistance and preventing platelet aggregation driven by serotonin, the drug helps alleviate symptoms like leg pain during walking and accelerates wound healing in diabetic foot ulcers. The pharmacokinetic profile shows rapid absorption after oral administration, with peak plasma concentrations reached within two hours. Metabolism occurs mainly in the liver via cytochrome P450 enzymes, and the active metabolites contribute significantly to its therapeutic duration.
Common side effects are generally mild and may include gastrointestinal disturbances such as nausea, abdominal discomfort, or diarrhea. Rare instances of elevated liver enzymes have been reported, necessitating periodic monitoring during long-term therapy. While it does not carry the same bleeding risks as anticoagulants, caution is advised when combining Sarpogrelate with other antithrombotic agents. Overall, Sarpogrelate represents a targeted therapeutic option that addresses the specific pathophysiology of serotonin-mediated vascular disorders, offering improved quality of life for patients suffering from chronic limb ischemia without the broad systemic effects of traditional antiplatelet drugs. Its unique selectivity makes it a cornerstone in modern vascular medicine protocols across various regions.